Floatz logo

Tolvaptan

Inappropriate ADH Syndrome

King's College Hospital NHS TrustSmall moleculePhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Inappropriate ADH Syndrome cohort.

Asset / SponsorPhaseRating
Empagliflozin
University Hospital, Basel, Switzerland
Phase 4BB
Satavaptan Monophosphate
Sanofi
Phase 3BB
Lixivaptan
CardioKine Inc.
Phase 3BB
Satavaptan
Sanofi
Phase 3B
Urea
Helbert Rondon Berrios, MD, MS
Phase 2CCC

Same molecule, other indications

Tolvaptan is also rated in:

cirrhosis of liverActive
BBB
Indicative · Phase 4
76 / 100
View asset →
water intoxicationDormant
BB
Indicative · Phase 3
68 / 100
View asset →
mineral metabolism diseaseDormant
BB
Indicative · Phase 3
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →